|
PT90657B
(pt)
|
1988-05-27 |
1995-03-01 |
Ortho Pharma Corp |
Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
|
|
JPH0768273B2
(ja)
*
|
1988-12-02 |
1995-07-26 |
カルピス食品工業株式会社 |
抗ｈｉｖペプチド
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
WO1990013562A1
(en)
|
1989-05-02 |
1990-11-15 |
Genelabs Incorporated |
Chemically modified cd4 peptide fragments having anti-retroviral properties
|
|
US5690933A
(en)
|
1989-05-31 |
1997-11-25 |
Glaxo Wellcome Inc. |
Monoclonal antibodies for inducing tolerance
|
|
GB8912497D0
(en)
|
1989-05-31 |
1989-07-19 |
Cobbold Stephen P |
Monoclonal antibodies
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US20020099179A1
(en)
|
1989-12-21 |
2002-07-25 |
Linda K. Jolliffe |
Cdr-grafted antibodies
|
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
|
US5871732A
(en)
|
1990-11-27 |
1999-02-16 |
Biogen, Inc. |
Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
JPH05244982A
(ja)
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化ｂ−ｂ１０
|
|
US5777085A
(en)
|
1991-12-20 |
1998-07-07 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with GPIIB/IIIA
|
|
IL101769A
(en)
|
1992-05-03 |
2007-02-11 |
Yeda Res & Dev |
Modulation of TNF receptor action
|
|
US5741488A
(en)
|
1992-10-08 |
1998-04-21 |
The Kennedy Institute For Rheumatology |
Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
|
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
DE122009000074I1
(de)
|
1993-03-05 |
2011-12-01 |
Bayer Healthcare Ag |
Humane monoklonale anti-TNF alpha Antikorper.
|
|
EP0631783A1
(en)
|
1993-06-03 |
1995-01-04 |
Mitsubishi Chemical Corporation |
Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
|
|
JPH09510952A
(ja)
|
1993-10-06 |
1997-11-04 |
ザ ケネディー インスティチュート オブ リューマトロジー |
自己免疫疾患および炎症性疾患の治療
|
|
US20020068057A1
(en)
|
1994-03-10 |
2002-06-06 |
Marc Feldmann |
Treatment of autoimmune and inflammatory disorders
|
|
JPH11505251A
(ja)
|
1995-05-18 |
1999-05-18 |
オーソ・フアーマシユーチカル・コーポレーシヨン |
非枯渇性抗ｃｄ４抗体の使用による免疫寛容の誘導
|
|
BRPI9707379C8
(pt)
|
1996-02-09 |
2017-12-12 |
Abbott Biotech Ltd |
composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
|
|
US20010056066A1
(en)
|
1996-07-26 |
2001-12-27 |
Smithkline Beecham Corporation |
Method of treating immune cell mediated systemic diseases
|
|
AU4563197A
(en)
|
1996-10-01 |
1998-04-24 |
Celltech Therapeutics Limited |
Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
DE19722888A1
(de)
|
1997-05-28 |
1998-12-03 |
Thomas Prof Dr Huenig |
Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
|
|
WO2000058362A1
(en)
|
1999-03-26 |
2000-10-05 |
Human Genome Sciences, Inc. |
Neutrokine-alpha binding proteins and methods based thereon
|
|
KR20020020730A
(ko)
|
1999-06-09 |
2002-03-15 |
오트리브 데이비스 더블유 |
Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료
|
|
WO2001016182A2
(en)
*
|
1999-08-27 |
2001-03-08 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
|
|
US7304127B2
(en)
|
1999-08-27 |
2007-12-04 |
United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
|
|
EP1289554A4
(en)
|
2000-06-02 |
2004-05-26 |
Univ Minnesota |
IMMUNOTHERAPEUTIC METHOD FOR PREVENTING REPELLATION OF ISLAND CELLS
|
|
KR20040023565A
(ko)
|
2000-09-18 |
2004-03-18 |
아이덱 파마슈티칼즈 코포레이션 |
Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
DK2314293T3
(en)
|
2001-01-16 |
2017-04-18 |
Vascular Therapies Llc |
IMPLANTABLE DEVICE CONTAINING RESORBABLE MATERIAL MATERIAL AND RAPAMYCINE FOR PREVENTION OR TREATMENT OF VASCULOPROLIFERATIVE DISEASES
|
|
US7125679B2
(en)
|
2001-03-07 |
2006-10-24 |
Children's Medical Center Corporation |
Methods to screen peptide libraries using minicell display
|
|
EP1241249A1
(en)
|
2001-03-12 |
2002-09-18 |
Gerold Schuler |
CD4+CD25+regulatory T cells from human blood
|
|
EP1381384B1
(en)
|
2001-04-24 |
2011-05-25 |
Merck Patent GmbH |
COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
|
|
WO2002102853A2
(en)
|
2001-06-14 |
2002-12-27 |
Isis Innovation Limited |
Cd4-specific antibody trx1 and uses therefor
|
|
US7541443B2
(en)
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
|
GB2376466A
(en)
|
2001-06-14 |
2002-12-18 |
Mark Frewin |
TRX1 antibody
|
|
ES2392287T3
(es)
|
2001-12-04 |
2012-12-07 |
Theramab Llc |
Péptido o proteína que contiene un bucle C'-D de la familia de receptores de la CD28
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
EP2444409A2
(en)
|
2002-09-16 |
2012-04-25 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
US7501494B2
(en)
|
2003-01-15 |
2009-03-10 |
United Biomedical, Inc. |
Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
|
|
EP1460088A1
(en)
*
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
MXPA05010778A
(es)
|
2003-04-09 |
2005-12-12 |
Genentech Inc |
Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
|
|
GB0314461D0
(en)
|
2003-06-20 |
2003-07-23 |
Isis Innovation |
Suppression of transplant rejection
|
|
US7691970B2
(en)
|
2003-08-25 |
2010-04-06 |
Pieris Ag |
Muteins of a bilin-binding protein with affinity for a given target
|
|
EP1600164A3
(de)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
CN101006100A
(zh)
|
2004-06-22 |
2007-07-25 |
托勒克斯股份有限公司 |
最优化地定量施用抗－cd4抗体用于在灵长类动物中诱导耐受性
|
|
AU2005270078A1
(en)
|
2004-07-02 |
2006-02-09 |
Genentech, Inc. |
Compositions and methods for treatment of non-hodgkin's lymphoma
|
|
WO2006035876A1
(ja)
|
2004-09-29 |
2006-04-06 |
Kowa Co., Ltd. |
関節リウマチの予防及び／又は治療薬
|
|
EP2171060B1
(de)
|
2004-11-11 |
2013-10-02 |
TheraMAB LLC |
Superagonistische anti-cd28 antikörper
|
|
US8119589B2
(en)
|
2004-11-12 |
2012-02-21 |
University Of North Carolina At Charlotte |
Modulation of CD4+ T cell responses by a tick saliva protein, Salp15 and polypeptides derived therefrom
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
JP4730733B2
(ja)
|
2005-05-02 |
2011-07-20 |
国立大学法人京都大学 |
４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
|
|
WO2007009064A2
(en)
|
2005-07-11 |
2007-01-18 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
KR20080039999A
(ko)
|
2005-08-18 |
2008-05-07 |
젠맵 에이/에스 |
Ｃｄ４ 결합 펩티드 및 방사선을 이용한 치료
|
|
NO345919B1
(no)
|
2005-08-26 |
2021-10-18 |
Roche Glycart Ag |
Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
|
|
JP5164856B2
(ja)
|
2006-01-05 |
2013-03-21 |
ジェネンテック， インコーポレイテッド |
抗ｅｐｈｂ４抗体およびその使用方法
|
|
AU2007227609A1
(en)
|
2006-03-16 |
2007-09-27 |
Genentech, Inc. |
Methods of treating lupus using CD4 antibodies
|
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
|
US20090208471A1
(en)
|
2006-04-07 |
2009-08-20 |
Yun Theodore J |
Isolation and Use of Human Regulatory T Cells
|
|
BRPI0710826A2
(pt)
|
2006-04-21 |
2011-08-23 |
Novartis Ag |
composições farmacêuticas de anticorpo anti-cd40 antagonista
|
|
WO2007135684A2
(en)
*
|
2006-05-22 |
2007-11-29 |
Hadasit Medical Research Services & Development Limited |
Method of treatment of anti-cd4 autoimmunity
|
|
ES2593789T3
(es)
|
2007-02-01 |
2016-12-13 |
Universitätsmedizin Der Johannes Gutenberg-Universität Mainz |
Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia
|
|
EP2599791A1
(en)
|
2007-04-27 |
2013-06-05 |
Genentech, Inc. |
Potent, stable and non-immunosuppressive anti-CD4 antibodies
|
|
KR20100135257A
(ko)
|
2008-03-13 |
2010-12-24 |
바이오테스트 아게 |
질병 치료제
|
|
ES2610327T3
(es)
*
|
2008-03-13 |
2017-04-27 |
Biotest Ag |
Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
|
|
ES2569217T3
(es)
*
|
2008-03-13 |
2016-05-09 |
Biotest Ag |
Agente para tratar enfermedades
|
|
EP2101173A1
(en)
|
2008-03-14 |
2009-09-16 |
Vivalis |
In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
|
|
US8951793B2
(en)
|
2008-08-21 |
2015-02-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of making an isolated population of FOXP3+ regulatory T cells
|
|
ES2335381B1
(es)
|
2008-09-24 |
2011-02-28 |
Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron |
Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
|
|
DK2341937T3
(en)
|
2008-09-29 |
2015-02-09 |
Biotest Ag |
Composition for the treatment of a disease
|
|
ES2351456B1
(es)
|
2009-06-24 |
2011-11-28 |
Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron |
Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b
|
|
JP5399219B2
(ja)
|
2009-11-24 |
2014-01-29 |
株式会社ケイティーバイオ |
関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
|
|
WO2011158798A1
(ja)
|
2010-06-14 |
2011-12-22 |
国立大学法人山口大学 |
乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット
|